JAK1 and chronic kidney disease: In FA‐ or UUO‐induced CKD models, BLI targets JAK1 and inhibits its phosphorylation and activation of the JAK‐STAT signaling pathway, thereby inhibiting multiple downstream events that promote kidney fibrosis.